 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19915 News |  |
| «12...192193194195196197198199200201202...203204» |
- |||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open, P4 data: PREDICTRA: A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects (clinicaltrials.gov) - Nov 19, 2014
P4, N=334, Recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting
- |||||| Tremfya (guselkumab) / J&J
Enrollment open: VOYAGE 2: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment (clinicaltrials.gov) - Nov 19, 2014
P3, N=1000, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment closed, Trial primary completion date: REDES-TNF: Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF (clinicaltrials.gov) - Nov 18, 2014
P4, N=190, Active, not recruiting, Sponsor: Spanish Clinical Pharmacology Society
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Apr 2015
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE) (clinicaltrials.gov) - Nov 18, 2014
P=N/A, N=548, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Apr 2015 Active, not recruiting --> Completed
- | Humira (adalimumab) / Eisai, AbbVie
Trial completion, Trial primary completion date: INTASAH: Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing (clinicaltrials.gov) - Nov 17, 2014
P4, N=30, Completed, Sponsor: Regionshospitalet Silkeborg
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Jul 2014 --> Jun 2013
- || clazakizumab (CSL300) / CSL Behring
P2b data, Trial primary completion date: Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate (clinicaltrials.gov) - Nov 6, 2014
P2b, N=418, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed | Trial primary completion date: Jul 2014 --> Jun 2013 Trial primary completion date: Sep 2012 --> Dec 2013
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice (clinicaltrials.gov) - Nov 6, 2014
P=N/A, N=550, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Sep 2012 --> Dec 2013 Recruiting --> Active, not recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, HEOR: Impact of Adalimumab (Humira) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice (clinicaltrials.gov) - Nov 6, 2014
P=N/A, N=460, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Humira (adalimumab) / Eisai, AbbVie
Enrollment open, Surgery: PUCCINI: Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease (clinicaltrials.gov) - Nov 5, 2014
P=N/A, N=1000, Recruiting, Sponsor: Mount Sinai School of Medicine
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Humira (adalimumab) / AbbVie
Enrollment closed, Trial primary completion date, HEOR: A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting (clinicaltrials.gov) - Oct 30, 2014
P3, N=455, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Apr 2015
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease (clinicaltrials.gov) - Oct 22, 2014
P4, N=60, Recruiting, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Apr 2015 Trial primary completion date: Jan 2016 --> Sep 2016
- || Xeljanz (tofacitinib) / Pfizer
Clinical: ORAL STRATEGY: An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate (clinicaltrials.gov) - Oct 22, 2014
P3, N=1080, Recruiting, Sponsor: Pfizer
Trial primary completion date: Jan 2016 --> Sep 2016 Phase classification: P4 --> P3
- | Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date, HEOR, Combination therapy: FOURIER: Adalimumab in the Treatment of Chronic Pouchitis (clinicaltrials.gov) - Oct 17, 2014
P3, N=24, Recruiting, Sponsor: Odense University Hospital
Phase classification: P4 --> P3 Trial primary completion date: Jun 2014 --> Sep 2015
- |||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Humira (adalimumab) / Eisai, AbbVie
Trial completion, Trial primary completion date, Pneumococcal vaccines: Efficacy Study of Pneumococcal Vaccination in Crohn's Disease (clinicaltrials.gov) - Oct 17, 2014
P4, N=197, Completed, Sponsor: Kyunghee University Medical Center
Trial primary completion date: Jun 2014 --> Sep 2015 Recruiting --> Completed | Trial primary completion date: Jan 2013 --> Jun 2013
- |||| Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: Visual II: Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis (clinicaltrials.gov) - Oct 15, 2014
P3, N=250, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed | Trial primary completion date: Jan 2013 --> Jun 2013 Trial primary completion date: Oct 2014 --> Feb 2015
- | Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease (clinicaltrials.gov) - Oct 15, 2014
P3, N=28, Active, not recruiting, Sponsor: AbbVie
Trial primary completion date: Oct 2014 --> Feb 2015 Recruiting --> Active, not recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Enrollment change, Trial primary completion date: PASSION: Observational Study to Explore the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP) (clinicaltrials.gov) - Oct 15, 2014
P=N/A, N=1000, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=1500 --> 1000 | Trial primary completion date: Nov 2016 --> Mar 2016
- |||||| etrolizumab (RG7413) / Roche
Enrollment open: HIBISCUS II: A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Oct 15, 2014
P3, N=350, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=1500 --> 1000 | Trial primary completion date: Nov 2016 --> Mar 2016 Not yet recruiting --> Recruiting
- |||||| etrolizumab (RG7413) / Roche
Enrollment open: HIBISCUS I: A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Oct 15, 2014
P3, N=350, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Humira (adalimumab) / Eisai, AbbVie
New P4 trial: Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial (clinicaltrials.gov) - Oct 4, 2014
P4, N=68, Not yet recruiting, Sponsor: Schneider Children's Medical Center, Israel
- Humira (adalimumab) / Eisai, AbbVie
Enrollment change, Trial termination, Trial primary completion date: Rheumatoid Arthritis Patients on Adalimumab to Evaluate Its Effect on Synovitis Using Ultrasonography in an Egyptian Population (clinicaltrials.gov) - Sep 30, 2014
P=N/A, N=12, Terminated, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting N=60 --> 12 | Recruiting --> Terminated | Trial primary completion date: Feb 2015 --> Jul 2014; This study was prematurely terminated due to low enrollment.
- Humira (adalimumab) / Eisai, AbbVie
Clinical: Effect of Anti-Inflammatory Agents on Biological Responses to Endotoxin Inhalation in Healthy Subjects (clinicaltrials.gov) - Sep 30, 2014
P0, N=51, Completed, Sponsor: Brugmann University Hospital
- ||||| Olumiant (baricitinib) / Incyte, Eli Lilly
Enrollment closed: RA-BEAM: A Study in Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Sep 28, 2014
P3, N=1280, Active, not recruiting, Sponsor: Eli Lilly and Company
N=60 --> 12 | Recruiting --> Terminated | Trial primary completion date: Feb 2015 --> Jul 2014; This study was prematurely terminated due to low enrollment. Recruiting --> Active, not recruiting
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open, P4 data: A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) (clinicaltrials.gov) - Sep 22, 2014
P=N/A, N=1300, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | New P4 trial, Surgery: Anti-TNFα Use During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 19, 2014
P4, N=660, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de Québec, CHU de Québec
- | Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: ADJUVITE: Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis (clinicaltrials.gov) - Sep 16, 2014
P2/3, N=34, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Enbrel (etanercept) / Pfizer, Amgen
Phase classification: ANTIBODY-RA: Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab (clinicaltrials.gov) - Sep 12, 2014
P=N/A, N=600, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Phase classification: P4 --> P=N/A
- |||| Xeljanz (tofacitinib) / Pfizer
Clinical: ORAL STRATEGY: An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate (clinicaltrials.gov) - Sep 11, 2014
P4, N=1080, Recruiting, Sponsor: Pfizer
Phase classification: P4 --> P=N/A Not yet recruiting --> Recruiting
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open, Enrollment change, Trial primary completion date, Adherence: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice (clinicaltrials.gov) - Aug 28, 2014
P=N/A, N=140, Recruiting, Sponsor: AbbVie
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting | N=80 --> 140 | Trial primary completion date: Feb 2015 --> Jul 2016
- ||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment closed, Trial primary completion date: RA-COMPARE: An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate (clinicaltrials.gov) - Aug 22, 2014
P3, N=700, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Recruiting | N=80 --> 140 | Trial primary completion date: Feb 2015 --> Jul 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Dec 2014
- || Enrollment closed: Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents (clinicaltrials.gov) - Aug 19, 2014
P=N/A, N=90, Active, not recruiting, Sponsor: University of Aarhus
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2016 --> Dec 2014 Recruiting --> Active, not recruiting
- fletikumab (NNC109-0012) / Novo Nordisk
Enrollment change, Trial withdrawal, Biopsy: A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate (clinicaltrials.gov) - Aug 15, 2014
P2, N=0, Withdrawn, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting N=42 --> 0 | Not yet recruiting --> Withdrawn
- Humira (adalimumab) / Eisai, AbbVie
Trial completion, Enrollment change: A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=29, Completed, Sponsor: Dr. FRANCISCO J. BLANCO-GARCIA
N=42 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed | N=168 --> 29
- ||| Humira (adalimumab) / AbbVie
Enrollment open, HEOR: Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo (clinicaltrials.gov) - Aug 7, 2014
P=N/A, N=70, Recruiting, Sponsor: AbbVie
Active, not recruiting --> Completed | N=168 --> 29 Not yet recruiting --> Recruiting
- |||||||||| Tremfya (guselkumab) / J&J
New P3 trial: VOYAGE 2: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment (clinicaltrials.gov) - Aug 4, 2014
P3, N=1000, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- |||||||||| Tremfya (guselkumab) / J&J
New P3 trial: VOYAGE 1: A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis (clinicaltrials.gov) - Aug 4, 2014
P3, N=750, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab (clinicaltrials.gov) - Aug 1, 2014
P=N/A, N=500, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Adalimumab BS MA (adalimumab biosimilar) / Mochida, LG Chem
New P1 trial: Pharmacokinetics and Safety Study of LBAL in Healthy Subjects (clinicaltrials.gov) - Aug 1, 2014
P1, N=116, Not yet recruiting, Sponsor: LG Life Sciences
- |||| Humira (adalimumab) / Eisai, AbbVie
Clinical: Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis (clinicaltrials.gov) - Jul 27, 2014
P3, N=800, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Trial primary completion date: Jun 2014 --> May 2016
- |||| Humira (adalimumab) / AbbVie
Trial primary completion date, HEOR: A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting (clinicaltrials.gov) - Jul 27, 2014
P3, N=455, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Jun 2014 --> May 2016 Trial primary completion date: Jun 2014 --> Jul 2015
- || Enbrel (etanercept) / Pfizer, Amgen
Trial primary completion date: ANTIBODY-RA: Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab (clinicaltrials.gov) - Jul 24, 2014
P4, N=600, Recruiting, Sponsor: Pfizer
Trial primary completion date: Jun 2014 --> Jul 2015 Trial primary completion date: Jun 2014 --> Dec 2014
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial initiation date: Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab (clinicaltrials.gov) - Jul 24, 2014
P2, N=100, Completed, Sponsor: AbbVie Deutschland GmbH & Co. KG
Trial primary completion date: Jun 2014 --> Dec 2014 Initiation date: Dec 2012 --> Mar 2013
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P4 trial, P4 data: PREDICTRA: A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects (clinicaltrials.gov) - Jul 24, 2014
P4, N=334, Not yet recruiting, Sponsor: AbbVie
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis (clinicaltrials.gov) - Jul 24, 2014
P4, N=106, Active, not recruiting, Sponsor: Innovaderm Research Inc.
Initiation date: Dec 2012 --> Mar 2013 Recruiting --> Active, not recruiting
- | Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date: A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease (clinicaltrials.gov) - Jul 23, 2014
P3, N=28, Recruiting, Sponsor: AbbVie
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Mar 2015
- || Humira (adalimumab) / Eisai, AbbVie
P4 data, Trial primary completion date: Complete-PS: Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=660, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Dec 2014 --> Mar 2015 Trial primary completion date: Jun 2018 --> Jun 2017
- || Humira (adalimumab) / Eisai, AbbVie
Trial primary completion date, HEOR: AGIL: Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=4500, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Jun 2018 --> Jun 2017 Trial primary completion date: Jul 2018 --> Dec 2018
- || Humira (adalimumab) / Eisai, AbbVie
P4 data, Trial initiation date: A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=1300, Not yet recruiting, Sponsor: AbbVie
Trial primary completion date: Jul 2018 --> Dec 2018 Initiation date: Apr 2014 --> Jul 2014
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
New P3 trial, Real-world evidence, Real-world: Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study (clinicaltrials.gov) - Jul 23, 2014
P3, N=200, Recruiting, Sponsor: AbbVie
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: VISUAL l: Efficacy and Safety of Adalimumab in Patients With Active Uveitis (clinicaltrials.gov) - Jul 23, 2014
P3, N=239, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Initiation date: Apr 2014 --> Jul 2014 Active, not recruiting --> Completed